by Five Rivers Rx | May 9, 2019 | Industry News
The State of New York recently passed into law Assembly Bill A9507C, a seemingly mundane bill concerning “major components of legislation necessary to implement the state health and mental hygiene budget for the 2018-2019 state fiscal year.”¹ However, this bill may...
by Five Rivers Rx | May 9, 2019 | Industry News
We have received a lot of questions over the past few weeks on how the lawsuit is progressing and what it will mean for the industry. Although we do not have any definitive answers yet (a court decision could come as early as June), we do have some highlights from our...
by Five Rivers Rx | Apr 10, 2019 | Industry News
Demetra Ashley spent three decades at the DEA specializing in the diversion of prescription drugs like OxyContin. Last spring, she left to start a consulting firm called Dashley Consulting, LLC. She has since been engaged by Purdue Pharma, the family-owned maker of...
by Five Rivers Rx | Mar 13, 2019 | Industry News
The Big 3 consolidated into the behemoths they are today through the 1990s and early 2000s. With so much volume being captured, the Big 3 gained the power to control the relationship they have with generic drug manufacturers. A few examples include: “Most Favored...
by Five Rivers Rx | Feb 12, 2019 | Industry News, VAWD
By now, OptumRx’s VAWD Accreditation requirement has become a ubiquitous part of the requirements for doing business in the pharmaceutical supply chain. In reading the policy, however, the requirements are not clear for manufacturers and those companies subject to...
by Five Rivers Rx | Jan 15, 2019 | Competition, Industry News
Background Five Rivers RX first released the story of the four major hospitals announcing that they’re coming together to launch a drug manufacturer in March of 2018 (click here for the article). Less than a year later, Civica is officially chartered,...
